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To investigate the respective role of transduced cells in the induction of immune response following intramuscular
inoculation of adenovirus-based vaccines, we generated several replication-defective adenoviruses expressing the glycopro-
tein D gene of pseudorabies virus under the control of four different promoters: major late promoter of adenovirus type 2,
human cytomegalovirus immediate-early promoter/enhancer (CMV), Rous sarcoma virus-long terminal repeat promoter, and
human desmin gene 5* regulatory region (DES). All the adenovirus constructs were able to fully protect mice, in the contrary
of direct DNA inoculation of plasmids harboring the same transcription units. The far most effective adenovirus constructs,
on the criterion of protective doses and specific antibody response induction, were those in which the foreign gene was
driven by the DES or CMV promoter. Wide variations in promoter strength in vitro were evidenced in several cell culture
types representative of putative target cells following muscular inoculation (myoblasts, myotubes, fibroblasts, macrophages,
and endothelial cells). The level of efficacy in vivo, was not correlated with the level of expression in vitro in myotubes, but
paralleled the level of expression in endothelial cells and in myoblasts. Together with previously published data, these
results suggest that, following adenovirus injection, locally produced cytokines may induce myoblasts to act as local antigen
presenting cells. q 1997 Academic Press
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INTRODUCTION ickan et al., 1995), hepatitis B (Davis et al., 1994), and
rabies virus (Xiang et al., 1995).
Recombinant vectors based on type 5 human adenovi- One on the main differences between plasmid- and
ruses (Ad5) have been developed either as replication adenovirus-mediated gene transfer rely on the target
competent (Both et al., 1993; Caravokyri et al., 1993; Pre- cells expressing the foreign protein. The primary target
vec et al., 1989) or as replication defective viruses (Ballay cells for transfection upon i.m. inoculation of plasmid
et al., 1987; Eloit et al., 1990a; Caravokyri, 1993; Ragot DNA are differentiated muscular cells, but their role in
et al., 1993; Xu et al., 1995). Replication defective adenovi- stimulating a naive immune system, remains unclear. On
ruses are based on replacement or deletion of the early the contrary, adenoviruses have a broad host cell range
region 1 (E1), in such a way that the viral cycle is blocked and can infect a wide spectrum of cells including quies-
in the early phase and the viral DNA persists in an extra- cent or terminally-differentiated cells (for a review see
chromosomic state. Intramuscular (i.m.) injection of plas- Ali et al., 1994; Gerard and Meidell, 1993; Randrianarison-
mid DNA vector also results in the production of a foreign Jewtoukoff and Perricaudet, 1995). Nevertheless, little is
protein that can serve as an antigen to stimulate humoral known on the respective role of each kind of transduced
and/or cellular immune responses in the injected host cells in eliciting an immune response, which precludes
(Ulmer et al., 1993; Wolff et al., 1990). The feasibility of any rational improvement of adenovirus vectors used for
using direct DNA injection as a vaccination approach vaccination purposes.
was first demonstrated in mice using the gene encoding We reasoned that a way to define such important cells
the influenza virus nucleoprotein (Ulmer et al., 1993). Sub- could be to measure protective doses of several recombi-
sequently, other groups have developed DNA vaccines nant adenoviruses expressing an immunogenic protein
for a variety of viral infections like herpes simplex (Man- under the control of various promoters and to analyze
if efficacy could be correlated to protein expression in
putative target cells. We used as a model the gD gene1 Present address: Laboratory of Genotoxic Agents, Ruder Bos˘kovic
of pseudorabies virus (PRV) because it is able to induce aInstitute, Bijenicka 54, 10000 Zagreb, Croatia.
protective immune response after challenge. Monoclonal2 To whom correspondence should be addressed. Fax: 33 1 43 96
71 31. E-mail: eloit@vet-alfort.fr. antibodies to gD were shown to neutralize PRV in vitro
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(Eloit et al., 1988; Wathen and Wathen, 1984) and pas- promoter/enhancer was isolated from pCMV-b (Clon-
tech, Palo Alto, CA). Plasmid pOP13CAT (Stratagene, Lasively protect mice (Marchioli et al., 1988). Some of them
were shown to block the penetration of the virus into Jolla, CA) contains the Rous sarcoma virus long terminal
repeat (RSV-LTR). The plasmid HuDes1000CAT (Li andcells (Eloit et al., 1990b). Vaccination of mice or pigs with
purified or recombinant gD (Ishii et al., 1988; Marchioli Paulin, 1991) contains 1 kb 5*-upstream regulatory region
of the human desmin gene followed by the coding regionet al., 1987) or with recombinant viral vector expressing
the gD gene (Adam et al., 1994; Brockmeier et al., 1993; of the CAT gene.
All inserts were confirmed by restriction enzyme map-Eloit et al., 1990a; Eloit and Adam, 1995; Ganne et al.,
1994; Marchioli et al., 1987; Riviere et al., 1992) were ping. Plasmids were propagated in Escherichia coli
DH5a (GIBCO Laboratories, Grand Island, NY). Plasmideffective.
We describe here immunization of mice with replica- stocks were prepared by standard maxipreparation pro-
cedures using Qiagen DNA purification columns (Qiagen,tion-defective adenoviruses expressing the gD of PRV
under the control of four different promoters: major late Hilden, Germany), according to the manufacturer’s in-
structions, and dissolved after alcohol precipitation inpromoter of adenovirus type 2 (MLP) (Kaufman, 1985)
the human cytomegalovirus immediate-early promoter/ phosphate buffered saline (pH 7.4).
enhancer (CMV) (Boshart et al., 1985), Rous sarcoma
virus-long terminal repeat promoter (RSV-LTR) (Gorman Cells and viruses
et al., 1982), and human desmin gene 5* regulatory re-
gion, containing muscle specific promoter, inhibitory re- The cell line 293, an adenovirus-transformed human
embryonic cell line, which provides phenotypic comple-gion, and enhancer (DES) (Li and Paulin, 1991, 1993).
Wide variations in promoter strength in vitro were evi- mentation of the E1 genes (Graham et al., 1977), was
used for DNA transfection, adenovirus multiplication, anddenced in several cell types representative of putative
target cells following muscular inoculation (myoblasts, titration. This cells were grown in Dulbecco’s modified
Eagle’s medium (DMEM) containing 10% fetal calf serummyotubes, fibroblasts, macrophages, and endothelial
cells). When tested in mice, all the adenovirus constructs (GIBCO Laboratories, Grand Island, NY). The C2.7 mouse
cell line was derived from C2 myoblasts. C2.7 cells werewere able to fully protect mice, in the contrary of direct
DNA inoculation of plasmids harboring the same con- propagated in growth medium DMEM supplemented
with 15% FCS. Differentiation was induced by switchingstruction units. The far most effective adenovirus con-
structs were those in which the foreign gene was driven confluent cultures to nutrient-poor medium (DMEM sup-
plemented with 2% horse serum). The fibroblast (3T3)by the DES or CMV promoter. These viruses expressed
the highest level of protein in endothelial cells and in and mouse endothelial cells 129 (Schwartz et al., 1993)
were provided by Dr. Claude Delouis and were propa-myoblasts. In addition, the level of efficacy in vivo was
not correlated with the level of expression in myotubes. gated in DMEM supplemented with 10% FCS. The pri-
mary cell culture of peritoneal macrophages was ob-
tained from mice strain 129.MATERIALS AND METHODS
The construction of AdMLPgD (formerly referenced as
Plasmids
Adgp50; Eloit et al., 1990a) was previously described.
Recombinant adenoviruses were constructed from AdThe construction of plasmid pMLPgD (formerly refer-
enced as pMLPgp50.6) was previously described (Eloit dl327, an E3-deleted mutant of Ad5. Recombinant adeno-
viruses were obtained by DNA ligation between the largeet al., 1990a). This plasmid contains the extreme left end
of the Ad5 genome (nucleotides 1–455) carrying the ITR, ClaI fragment of Ad5 DNA and the different plasmids, as
previously described (Eloit et al., 1990a). After ligation,the encapsidation sequences and the enhancer of the
E1A promoter, the gD gene of the NIA-3 PRV strain under the DNA was transfected into 293 cells. Ten to fifteen
days later plaques were picked, expanded in 293 cellthe control of the major late promoter (MLP) of Ad2 joined
to its tripartite sequence (nucleotides 6041–6080, 7100– line, and viral DNA was extracted by the Hirt procedure
(Graham et al., 1977). Recombinant viruses were identi-7170, 9635–9725). The Simian Virus 40 (SV40) A gene
polyadenylation signal (nucleotides 2770–2553) follows fied by restriction analysis. Candidate viruses were
cloned twice, after which genetic stability was deter-the gD coding sequence without any splicing signals.
Plasmid pMLP10CAT contains the chloramphenicol mined by restriction analysis.
Adenoviruses were amplified on semiconfluent mono-acetyltransferase (CAT) gene followed by splicing (nucle-
otides 4705–4099) and polyadenylation (nucleotides layers of 293. Therefore adenoviruses were purified by
banding twice in CsCl density gradients to avoid the2770–2553) signals from SV40 cloned downstream from
the MLP and its tripartite sequence (Ballay et al., 1987). contamination of virus stocks with gD and were exten-
sively dialysed against PBS before inoculation. VaccineIn constructions of pCMVgD, pRSVgD, and pDESgD the
tripartite sequence was excised. doses were prepared by dilution of virus stocks in cold
salt solution just before inoculation.The human cytomegalovirus (CMV) immediate-early
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Immunoprecipitations plasmids pCMVgD, pRSVgD, and pDESgD that are
strictly isogenic except for the enhancer and promoterOne hour before infection of cell cultures with recombi-
regions. The promoter elements were first inserted intonant adenoviruses, minimum essential medium (MEM)
the plasmid pMLP10CAT. In constructions of pCMVCAT,was replaced by fresh medium without cysteine and me-
pRSVCAT, and pDESCAT the tripartite sequences of MLPthionine (GIBCO BRL). Cells were then infected with 30
were excised.TCID50 of recombinant adenovirus per cell. Radioactive
The human cytomegalovirus (CMV) immediate-earlylabeling was carried out with 50–100 mC/106 cells of
promoter/enhancer was isolated as a PstI–XhoI frag-ICN Trans-label 35S ([35S]methionine and [35S]cysteine).
ment from pCMV-b (Clontech, Palo Alto, CA) and insertedThree days later (except for the 129 cells for which infec-
into SacII– XhoI-digested pMLP10CAT after treatment oftion was interrupted after two days), cells were lysed
PstI and SacII sites with T4 DNA polymerase. The re-and precipitated with a gD-specific monoclonal antibody
sulting plasmid pCMVCAT was digested with PstI and(022M24-, Eloit et al., 1988) as previously described
XhoI and the fragment containing the CMV promoter ele-(Eloit et al., 1990b). After autoradiography, the film was
ment was ligated with PstI–XhoI fragment of thescanned and spot intensity was evaluated with NIH im-
pMLPgD, giving rise to plasmid pCMVgD.age software.
Plasmid pOP13CAT (Stratagene, La Jolla, CA) contains
the Rous sarcoma virus long terminal repeat (RSV-LTR).Vaccination with recombinant adenoviruses and
The SacII– HindIII fragment derived from pOP13CAT waschallenge with PRV
ligated with corresponding SacII– HindIII fragment of theOF1 mice (18 g weight) were obtained from IFFA-
pMLPCAT. The resulting plasmid pRSVCAT was digestedCREDO. Groups of six mice were injected i.m. at one site
with PstI and HindIII and this fragment was inserted be-in the thigh with vaccine doses of recombinant viruses
tween PstI and XhoI sites of pMLPgD (XhoI and HindIIIranging from 109 TCID50 to 10
5 TCID50 for AdMLPgD or sites were blunt ended with the Klenow polymerase),109 TCID50 to 10
4 TCID50 for AdCMVgD, AdRSVgD, and giving rise to plasmid pRSVgD.AdDESgD in a volume of 100 ml. Blood samples from each
The EcoRI–XhoI fragment from plasmid HuDes1000-animal were collected 3 and 5 weeks later. Animals were
CAT (Li and Paulin, 1991), containing the human desminchallenged intraperitonaly 5 weeks after vaccination, with
enhancer, inhibitory region, and the human desmin pro-200 ml of tissue culture medium containing 20 LD50 of the moter was placed between SacII and XhoI sites of thePRV Kojnock strain, previously titrated in the target spe-
pMLP10CAT (after filling in the EcoRI end with Klenowcies. Animals were then observed daily for 15 days.
polymerase and the treatment of SacII site with T4 DNA
polymerase) to give pDESCAT. The SphI–XhoI fragmentVaccination with plasmid DNA and challenge with PRV
from pDESCAT was inserted into the pMLPgD at appro-Groups of 10 OF1 mice (18 g weight) were injected
priate sites. The resulting plasmid was defined asintramuscularly (i.m.) at one site in the thigh with a total
pDESgD. All inserts were confirmed by restriction en-of 25, 50, or 100 mg of plasmids pMLPgD, pCMVgD,
zyme mapping.pRSVgD, and pDESgD. Four weeks later blood samples
To construct the recombinant adenoviruses AdRSVgD,from each animal were collected, and one half of each
AdCMVgD, and AdDESgD the same protocol as forgroup of animals were boosted with the same dose as
AdMLPgD (Eloit et al., 1990a) was employed, meaningon day 33. Mice were challenged 4 weeks later with
that the plasmid fragment which contains the gD gene20LD50 of the Kojnock strain of PRV, in 200 ml, by intraperi- was used to replace the extreme left end of Ad-dl327 bytoneal route. Animals were monitored daily.
ligation at the unique ClaI site. All constructions were
confirmed by restriction enzyme mapping. Figure 1 sum-Detection of neutralizing antibodies directed against gD
marizes these constructions.
Fifty microliters of serial dilutions of sera were mixed
with 100 TCID50 of PRV (strain Kojnok), incubated 4 h at
Expression of gD from different promoters in cell377, then overnight at 47. Six replicates were made for
cultureseach tested dilution. Pig kidney (PK15) cells were added
and c.p.e. were recorded 3 days later. Serum titers were
The level of expression of gD from promoters MLP,
expressed as the dilutions required to neutralize the in-
RSV, CMV, and DES was first compared in human 293
put virus in 50% of the replicates.
cells which support adenovirus replication. Cells were
infected with recombinant viruses using an m.o.i. of 30RESULTS
TCID50/cell. Radiolabeled gD was recovered by immuno-
Construction of plasmids and corresponding precipitation with a gD-specific monoclonal antibody and
recombinant adenoviruses proteins were analyzed after gel electrophoresis. The
expected band at 62 kDa was evidenced. The promotersThe constructions of pMLPgD and AdMLPgD were
previously described (Eloit et al., 1990a). We constructed did not vary greatly in activity (Fig. 2).
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FIG. 1. Genomic structure of: (a) plasmids pMLPgD, pRSVgD, pCMVgD, and pDESgD; (b) Ad-dl327 an E3-deleted mutant of adenovirus type 5.
For the construction of the recombinant viruses the PstI–ClaI fragment of pMLPgD (Eloit et al., 1990a), pRSVgD and pCMVgD or XmnI–ClaI fragment
of pDESgD was cloned at the ClaI unique site in Ad5-dl327. Key: Elt I and II, enhancer sequences of E1A; Al to AV, encapsidation sequences of
Ad5 (Grable and Hearing, 1993); MLP, major late promoter and three leader sequences of Ad2 (Kaufman, 1985); CMV, human cytomegalovirus
immediate-early promoter/enhancer (Boshart et al., 1985); RSV, Rous sarcoma virus-long terminal repeat promoter (Gorman et al., 1982); DES, human
desmin gene 5* regulatory region containing muscle specific promoter, inhibitory region and enhancer (Li and Paulin, 1991, 1993).
As human 293 cells support replication of recombinant In contrast, mice inoculated i.m. with different doses up
to 100 mg of plasmid DNA (pMLPgD, pRSVgD, pCMVgD,adenoviruses which are defective in the E1 region, it was
of interest to compare expression levels in noncomple- pDESgD) demonstrated no neutralizing antibody re-
sponse at D27. After a second injection at D33 in onementing cells. Those cells were chosen to match as
closely as possible putative target cells after i.m. inocula- half of each group, neutralizing antibody titers of sera
sampled at D60 remained negative. Some sera sampledtion (Fig. 2). No detectable expression could be seen for
MLP- and RSV-driven gD gene, even after long exposure at D27 and D60 and tested with a very sensitive ELISA
using a baculovirus-expressed gD as antigen (a gener-time (up to 3 months). A high level of expression was
detected for CMV and DES-driven gD in C2.7 myoblasts ous gift from Dr. M. Banks, Central Veterinary Laboratory,
New Haw, UK) demonstrated very low gD-specific anti-cells. In C2.7 myotubes, expression from the CMV pro-
moter was again high, while expression from the DES body response, without clear differences between doses
inoculated or regimes (not shown).promoter was barely detectable only after prolonged ex-
posure of photograph film to gel (3 weeks, data not
Protection against challenge with PRVshown). No expression was detected whatever the pro-
moter used in mouse peritoneal macrophages, used as
Vaccinated and control mice were challenged at 5a model of muscle macrophages, after a standard 3-days
weeks after the single injection of adenoviruses or 4exposition of the film (not shown). A 3-weeks exposure
weeks after the second injection of plasmids. All fourrevealed a low level of expression for only the CMV-
adenoviruses conferred complete protection against adriven gene (Fig. 2). Finally, no expression could be de-
lethal challenge dose of PRV, but the protective dosestected in 3T3 fibroblasts from any of the four promoters
50% (PD50) were very different (Table 1). For AdRSVgDtested.
and AdMLPgD, the PD50 were comparable (respectively,
8.1 and 8.9 log10 TCID50). The two other viruses gaveInduction of antibody response in mice following
similar but significantly (100- to 1000-fold) lower PD50plasmid or adenovirus inoculation
(AdDESgD, 6.2; AdCMVgD, 5.8).
Antibody response against gD was monitored in mice No protection was recorded after challenge for the
3 and 5 weeks after a unique inoculation of different mice in groups that received plasmids either as a single
doses of recombinant adenoviruses AdMLPgD, injection or as two injections.
AdRSVgD, AdCMVgD, and AdDESgD. As shown in Table
1, all recombinant adenoviruses elicited neutralizing anti- DISCUSSION
bodies as early as 3 weeks following inoculation and the
responses appeared to be dose-dependent. The neu- Ad vectors are being used increasingly for a variety of
applications of in vivo gene transfer, including vaccina-tralizing titers were greatest at 5 weeks after injection.
The most efficient viruses were AdCMVgD and Ad- tion. In this report, we studied antibody responses and
PD50 in mice after i.m. injection of several constructsDESgD, which gave at low doses antibody responses
similar to AdMLPgD or AdRSVgD used at 100- to 1000- differing only for the promoter used to drive the expres-
sion of the transgene. We found that the efficiency offold higher doses.
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FIG. 2. Expression of gD from various promoters in cells infected with recombinant adenoviruses. Infected cells were radiolabeled and harvested
3 days p.i. except 129 cells (2 days p.i.). The results presented are derived from an exposition time of 3 days, except for macrophages (3 weeks).
these vectored vaccines may vary by a factor of more at 3-week intervals with 100 mg of DNA. We tested the
antibody response of mice upon inoculation twice ofthan 100 relative to the promoter used.
We found lack of efficiency of DNA inoculation of plas- maximum 100 mg of DNA, at a 1-month interval. The
differential activity between adeno- and plasmid vac-mids harboring the same construction units, in eliciting
antibody response and protection, which is reminiscent cines seems likely dependent of the target-transduced
cells but may also vary in function of the transducedof similar results described with Herpes simplex virus
type 1 gD, the homologous glycoprotein to PRV gD, which gene.
Little is known to date about the mechanisms leadinginduces high titer of neutralizing antibodies to HSV-1 and
provides protection against lethal challenge of animals to induction of an immune response upon inoculation of
plasmid DNA or adenovirus vaccines. Transfection ofin a variety of systems of vaccination (Berman et al.,
1983; Cremer et al., 1985; Ghiasi et al., 1994; Metcalf et muscle cells has been demonstrated using plasmids car-
rying reporter genes (Wolff et al., 1990). The mono-al., 1988; Mishkin et al., 1991). However, intramuscular
injection of mice with HSV-1gD containing plasmids ap- nucleated dividing satellite cells do not seem to be in-
volved in plasmid uptake in vivo. On the other hand,peared to induce low levels of serum anti gD antibody,
low levels of anti HSV-1 neutralizing antibody, and low within the endomysial spaces of muscles injected with
adenovirus, a large number of small mononucleated cellslevel of protection against lethal challenge (Ghiasi et al.,
1995). Although HSV-1 gD can induce CTL responses were found, and a significant number of these expressed
the reporter gene from the adenovirus. These mono-(Johnson et al., 1990), they were not actually detected.
They used the same promoter CMV that was used for nucleated cells, which are not present in normal or re-
generating muscle injected with plasmid DNA were iden-our experiments, but the mice were injected three times
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TABLE 1
Antibody Responses after Vaccination and Protection after Challenge in Mice
AdMLPgD AdRSVgD AdCMVgD AdDESgD
Neutral. Neutral. Neutral. Neutral.
antibody antibody antibody antibody
titer week Animals titer week Animals titer week Animals week Animals
Virus dose protected protected protected protected
(log10) 3 5a (5 weeks) 3 5 (5 weeks) 3 5 (5 weeks) 3 5 (5 weeks)
0 (controls) 2 1/11b
4 ND ND ND 2 2 0/6 2 /8 3/6 2 2 1/6
5 2 2 1/6 2 2 0/2 /4 /8 3/6 2 2 2/6
6 2 2 2/6 2 8 0/6 /32 /32 4/6 2 2 2/6
7 2 2 1/6 2 2 0/6 /256 /512 6/6 /32 /32 6/6
8 2 2 1/6 2 2 1/6 /32 /256 5/6 /128 /256 6/6
9 /8 /16 6/6 /16 /32 6/6 /256 /1024 6/6 ND ND ND
PD50 — 8.9 — 8.1 — 5.8 — 6.2
Note. ND, not detected.
a Neutralizing antibody titer at time of challenge.
b Number of animals surviving/number of animals challenged.
tified as blood cells (Davis et al., 1993). Muscle cells of antigen-expressing muscle cells by cytotoxic T cells,
leading then to the release of antigen, also seems un-express only low levels of MHC class I antigens and,
without prior treatment with interferon g, show no MHC likely for DNA vaccines and probably for adenovirus vac-
cines because b2 microglobin knock-out mice (whichclass II antigen expression (Hohlfeld and Engel, 1994).
Thus, muscle cell does not represent typical antigen pre- therefore do not express MHC class I antigens at the
cell surface) developed T helper cells and antibody uponsenting cell. However, in most cases of DNA-based im-
munization antibodies have been found, the induction of immunization with plasmid vector-expressing rabies vi-
rus G protein at levels comparable to that in control miceCTL has been demonstrated as well as T-helper re-
sponse and the ‘‘challenge’’ studies on animals in several (Ertl et al., 1995).
The demonstration that adenoviruses differing only formodels have shown that protection can be obtained (Co-
ney et al., 1994; Cox et al., 1993; Davis et al., 1994; Fynan promoters used to drive the transcription of the foreign
gene differed strongly in vaccination efficacy permittedet al., 1993; Manickan et al., 1995; Okuda et al., 1995;
Schrimbeck et al., 1995; Ulmer et al., 1993; Wang et al., another approach to define target cells important for the
induction of an immune response after Ad inoculation.1993; Xiang et al., 1995; Yokoyama et al., 1995).
Recent experiments, dealing with mechanism of CTL We reasoned that such difference was likely related to
the level of expression of the foreign gene in adequatepriming (which includes MHC I presentation), indicate
that muscle cells at the site of plasmid DNA injection cells. Expression in these cells is controlled both by the
level of expression of Ad receptors at the cell surface,do not themselves present gene-encoded antigen to the
immune system. Furthermore, presentation occurs at the which governs the penetration of the virus genome, and
also by the activity of the promoters in these target cells.surface of professional bone marrow-derived APCs (Corr
et al., 1996). The PRV gD plays the important role in the Because all the constructs were derived from Ad5, the
effects seen could only be related to the level of tran-humoral immune response while its involvement in cell-
mediated immunity have not been shown (reviewed in scription from each promoter. In the objective to analyze
this parameter, we studied the level of expression in vitroMettenleiter, 1996). Up to now there is no evidence that
a similar mechanism works for MHC II presentation and of each construct in cells representative of putative target
cells after muscular injection.antibody production, but according to our results (i.e.,
failure of DNA vaccine) that seems unlikely. Xiang et al. In cultured myoblasts both AdCMVgD and AdDESgD
expressed high levels of gD, whereas in myotubes ex-(1995) showed that transfected muscle cells cannot
serve as an antigen reservoir, boosting the response by pression from AdCMVgD was strong but lower than in
myoblasts and expression from AdDESgD was barelysecreting or releasing antigen upon lysis due to cytolytic
T cells. The same result using an anchor-sequence de- detectable. It is well known that compared with myo-
blasts, transduction efficiency in myotubes is lower, dueleted glycoprotein and full-length membrane-bound gly-
coprotein was also demonstrated for an adenovirus vac- to a lower expression of avb5 and avb3 integrins, which
are the ligand of the penton base protein (Acsadi et al.,cine (Mittal et al., 1996). A mechanism involving the lysis
AID VY 8842 / 6a53$$$223 10-28-97 15:12:57 vira AP: VY
333ADENOVIRUS-VECTORED VACCINES
1994). Comparison of gD expressed in myoblast and my- imply the functional capacity of antigen presentation, but
Goebels et al. (1992) have shown that human myoblastsotubes after infection with AdCMVgD and AdDESgD
shows that the lack of expression of gD in myotubes treated with IFN-g can be induced to express the intra-
cellular adhesion molecule ICAM-1, in addition to HLA-after infection with AdDESgD was not due only to lower
infection efficiency in myotubes. The lack of expression DR, -DP, and -DQ, and that induced myoblasts can pre-
sent different protein antigens. So it is possible that lo-of the desmin promoter in myotubes was unexpected. It
has been previously reported that high level human des- cally produced cytokines may act on myoblasts and in-
duce them to act as local antigen presenting cells. It ismin expression depends on a 280-base pair muscle-
specific enhancer which can function not only in myo- also possible that dendritic cells expressing MHC class
II can recognize the foreign protein expressed by myo-tubes, but can also activate gene expression in myo-
blasts (Li and Paulin, 1993). We have found that in vitro, blasts or endothelial cells. In our hand Ad5 infection of
murine dendritic cells has proven very inefficient, sug-some cell cultures which are not of muscular origin (293,
endothelial 129 cells) infected with AdDESgD, expressed gesting that infection of these cells cannot explain the
results obtained. It is also possible that other cells asgD. The expression cassettes in all recombinant adenovi-
ruses were placed immediately downstream of the E1A lymphoid B cells can act also as secondary APC after
induction of the immune response. Nonactivatedenhancer in the left end of the viral genome. In agree-
ment with our results Babiss et al. (1986) observed only lymphoid cells are not permissive for adenovirus entry
but activation by hematopoietic growth factors is fol-a partial tissue specificity of the albumin and b-globin
promoters. Imler et al. (1996) were also unable to demon- lowed by the expression of adenovirus receptor and a
transition to a permissive state for adenovirus entry (Hu-strate a cell-type specificity of expression strictly parallel-
ing that of the endogenous human cystic fibrosis trans- ang et al., 1995). Nevertheless, Overell et al. (1991) dem-
onstrated that MLP and CMV driven genes were equallymembrane conductance regulator (CFTR) gene. Quantin
et al. (1992) confirmed the muscle specificity of the mus- expressed in primary murine B lymphocytes, which ren-
der the hypothesis of these cells acting as primary APCcle-specific regulatory sequences (enhancer fragment of
the mouse myosin light chain 1/3 locus and mouse skele- inconsistent with our results. In summary, our results,
together with previously published ones, suggest thattal a-actin gene promoter) by examing the b-gal activity
in infected 3T3 mouse fibroblast. We tested the gD ex- myoblasts could act as APC following intramuscular Ad
inoculation.pression in the same type of cells after infection with all
recombinants but expression could not be detected even To our knowledge this is the first report dealing with
the comparison of promoter efficacy in adenovirus-vec-after prolonged exposure of a photograph film to the gel.
Xu et al. (1995) investigated the expression of a rotavirus tored vaccines with their activity in representative target
cells. The results described in this report demonstrateantigen VP7sc, employing several commonly used pro-
moters carried in E1-substituted Ad vectors in different that the use of safer, replication defective adenoviruses
for vaccination can be improved by selecting adequatecell types and they also observed no expression in
mouse 3T3 fibroblasts. These results are likely related promoters. Further demonstration of the role of each cell
type can use a protocol based on their purification, into the poor infectability of 3T3 cells by Ad5. We confirmed
previous findings that due to the E1A enhancer, only vitro infection, and grafting in syngenic mice.
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